To include your compound in the COVID-19 Resource Center, submit it here.

Canbridge licenses Chinese rights to Puma's Nerlynx

Puma Biotechnology Inc. (NASDAQ:PBYI) granted Canbridge Life Sciences Ltd. (Beijing, China) exclusive rights to develop and commercialize cancer

Read the full 184 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE